Antagonistic activities of CDC14B and CDK1 on USP9X regulate WT1-dependent mitotic transcription and survival.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
09 03 2020
Historique:
received: 18 04 2019
accepted: 17 02 2020
entrez: 11 3 2020
pubmed: 11 3 2020
medline: 3 7 2020
Statut: epublish

Résumé

Regulation of mitosis secures cellular integrity and its failure critically contributes to the development, maintenance, and treatment resistance of cancer. In yeast, the dual phosphatase Cdc14 controls mitotic progression by antagonizing Cdk1-mediated protein phosphorylation. By contrast, specific mitotic functions of the mammalian Cdc14 orthologue CDC14B have remained largely elusive. Here, we find that CDC14B antagonizes CDK1-mediated activating mitotic phosphorylation of the deubiquitinase USP9X at serine residue 2563, which we show to be essential for USP9X to mediate mitotic survival. Starting from an unbiased proteome-wide screening approach, we specify Wilms' tumor protein 1 (WT1) as the relevant substrate that becomes deubiquitylated and stabilized by serine 2563-phosphorylated USP9X in mitosis. We further demonstrate that WT1 functions as a mitotic transcription factor and specify CXCL8/IL-8 as a target gene of WT1 that conveys mitotic survival. Together, we describe a ubiquitin-dependent signaling pathway that directs a mitosis-specific transcription program to regulate mitotic survival.

Identifiants

pubmed: 32152317
doi: 10.1038/s41467-020-15059-5
pii: 10.1038/s41467-020-15059-5
pmc: PMC7063047
doi:

Substances chimiques

CXCL8 protein, human 0
Interleukin-8 0
Transcription Factors 0
USP9X protein, human 0
WT1 Proteins 0
WT1 protein, human 0
CDC2 Protein Kinase EC 2.7.11.22
CDK1 protein, human EC 2.7.11.22
CDC14B protein, human EC 3.1.3.48
Dual-Specificity Phosphatases EC 3.1.3.48
Ubiquitin Thiolesterase EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1268

Références

Dominguez-Brauer, C. et al. Targeting mitosis in cancer: emerging strategies. Mol. Cell 60, 524–536 (2015).
doi: 10.1016/j.molcel.2015.11.006
Lischetti, T. & Nilsson, J. Regulation of mitotic progression by the spindle assembly checkpoint. Mol. Cell Oncol. 2, e970484 (2015).
doi: 10.4161/23723548.2014.970484 pubmed: 4905242 pmcid: 4905242
Lara-Gonzalez, P., Westhorpe, F. G. & Taylor, S. S. The spindle assembly checkpoint. Curr. Biol. 22, R966–R980 (2012).
doi: 10.1016/j.cub.2012.10.006
Manic, G., Corradi, F., Sistigu, A., Siteni, S. & Vitale, I. Molecular regulation of the spindle assembly checkpoint by kinases and phosphatases. Int. Rev. Cell Mol. Biol. 328, 105–161 (2017).
doi: 10.1016/bs.ircmb.2016.08.004
Watson, E. R., Brown, N. G., Peters, J. M., Stark, H. & Schulman, B. A. Posing the APC/C E3 ubiquitin ligase to orchestrate cell division. Trends Cell Biol. 29, 117–134 (2019).
doi: 10.1016/j.tcb.2018.09.007
Visintin, R. et al. The phosphatase Cdc14 triggers mitotic exit by reversal of Cdk-dependent phosphorylation. Mol. Cell 2, 709–718 (1998).
doi: 10.1016/S1097-2765(00)80286-5
Wurzenberger, C. & Gerlich, D. W. Phosphatases: providing safe passage through mitotic exit. Nat. Rev. Mol. Cell Biol. 12, 469–482 (2011).
doi: 10.1038/nrm3149
Stegmeier, F. & Amon, A. Closing mitosis: the functions of the Cdc14 phosphatase and its regulation. Annu. Rev. Genet. 38, 203–232 (2004).
doi: 10.1146/annurev.genet.38.072902.093051
Berdougo, E., Nachury, M. V., Jackson, P. K. & Jallepalli, P. V. The nucleolar phosphatase Cdc14B is dispensable for chromosome segregation and mitotic exit in human cells. Cell Cycle 7, 1184–1190 (2008).
doi: 10.4161/cc.7.9.5792
Bassermann, F. et al. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 134, 256–267 (2008).
doi: 10.1016/j.cell.2008.05.043 pubmed: 2591934 pmcid: 2591934
Wei, Z. et al. Early-onset aging and defective DNA damage response in Cdc14b-deficient mice. Mol. Cell Biol. 31, 1470–1477 (2011).
doi: 10.1128/MCB.01330-10 pubmed: 3135283 pmcid: 3135283
Oczko-Wojciechowska, M. et al. Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. Sci. Rep. 7, 42074 (2017).
doi: 10.1038/srep42074 pubmed: 5299608 pmcid: 5299608
Kim, Y., Choi, J. W., Lee, J. H. & Kim, Y. S. Loss of CDC14B expression in clear cell renal cell carcinoma: meta-analysis of microarray data sets. Am. J. Clin. Pathol. 141, 551–558 (2014).
doi: 10.1309/AJCP4PE4JPSRGBQS
Galeano, F. et al. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. Oncogene 32, 998–1009 (2013).
doi: 10.1038/onc.2012.125
Murtaza, M., Jolly, L. A., Gecz, J. & Wood, S. A. La FAM fatale: USP9X in development and disease. Cell Mol. Life Sci. 72, 2075–2089 (2015).
doi: 10.1007/s00018-015-1851-0 pubmed: 4427618 pmcid: 4427618
Schwickart, M. et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463, 103–107 (2010).
doi: 10.1038/nature08646 pubmed: 20023629 pmcid: 20023629
Vong, Q. P., Cao, K., Li, H. Y., Iglesias, P. A. & Zheng, Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 310, 1499–1504 (2005).
doi: 10.1126/science.1120160
Engel, K. et al. USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. EMBO Mol. Med. 8, 851–862 (2016).
doi: 10.15252/emmm.201506047 pubmed: 4967940 pmcid: 4967940
Skowyra, A., Allan, L. A., Saurin, A. T. & Clarke, P. R. USP9X limits mitotic checkpoint complex turnover to strengthen the spindle assembly checkpoint and guard against chromosomal instability. Cell Rep. 23, 852–865 (2018).
doi: 10.1016/j.celrep.2018.03.100 pubmed: 5917450 pmcid: 5917450
Palozola, K. C. et al. Mitotic transcription and waves of gene reactivation during mitotic exit. Science 358, 119–122 (2017).
doi: 10.1126/science.aal4671 pubmed: 5727891 pmcid: 5727891
Lodhi, N., Ji, Y. & Tulin, A. Mitotic bookmarking: maintaining post-mitotic reprogramming of transcription reactivation. Curr. Mol. Biol. Rep. 2, 10–16 (2016).
doi: 10.1007/s40610-016-0029-3 pubmed: 4813802 pmcid: 4813802
Teves, S. S. et al. A dynamic mode of mitotic bookmarking by transcription factors. Elife 5, https://doi.org/10.7554/eLife.22280 (2016).
Call, K. M. et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60, 509–520 (1990).
doi: 10.1016/0092-8674(90)90601-A
Gessler, M. et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343, 774–778 (1990).
doi: 10.1038/343774a0
Hastie, N. D. Wilms’ tumour 1 (WT1) in development, homeostasis and disease. Development 144, 2862–2872 (2017).
doi: 10.1242/dev.153163
Yang, L., Han, Y., Suarez Saiz, F. & Minden, M. D. A tumor suppressor and oncogene: the WT1 story. Leukemia 21, 868–876 (2007).
doi: 10.1038/sj.leu.2404624
Katuri, V. et al. WT1 regulates angiogenesis in Ewing Sarcoma. Oncotarget 5, 2436–2449 (2014).
doi: 10.18632/oncotarget.1610 pubmed: 4058017 pmcid: 4058017
Srivastava, A. et al. High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin. Cancer Res. 12, 4237–4243 (2006).
doi: 10.1158/1078-0432.CCR-05-2307
Wu, C. et al. WT1 promotes invasion of NSCLC via suppression of CDH1. J. Thorac. Oncol. 8, 1163–1169 (2013).
doi: 10.1097/JTO.0b013e31829f6a5f
Vicent, S. et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J. Clin. Invest. 120, 3940–3952 (2010).
doi: 10.1172/JCI44165 pubmed: 2965578 pmcid: 2965578
Mayo, M. W. et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J. 18, 3990–4003 (1999).
doi: 10.1093/emboj/18.14.3990 pubmed: 1171475 pmcid: 1171475
Hanson, J., Gorman, J., Reese, J. & Fraizer, G. Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front. Biosci. 12, 2279–2290 (2007).
doi: 10.2741/2230 pubmed: 2562899 pmcid: 2562899
McCarty, G., Awad, O. & Loeb, D. M. WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J. Biol. Chem. 286, 43634–43643 (2011).
doi: 10.1074/jbc.M111.310128 pubmed: 3243556 pmcid: 3243556
Lukas, C. et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat. Cell Biol. 13, 243–253 (2011).
doi: 10.1038/ncb2201
Tanguay, P. L., Rodier, G. & Meloche, S. C-terminal domain phosphorylation of ERK3 controlled by Cdk1 and Cdc14 regulates its stability in mitosis. Biochem. J. 428, 103–111 (2010).
doi: 10.1042/BJ20091604
Ji, M. et al. Phospho-regulation of KIBRA by CDK1 and CDC14 phosphatase controls cell-cycle progression. Biochem. J. 447, 93–102 (2012).
doi: 10.1042/BJ20120751
Holt, L. J. et al. Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution. Science 325, 1682–1686 (2009).
doi: 10.1126/science.1172867 pubmed: 2813701 pmcid: 2813701
Petrone, A., Adamo, M. E., Cheng, C. & Kettenbach, A. N. Identification of candidate cyclin-dependent kinase 1 (Cdk1) substrates in mitosis by quantitative phosphoproteomics. Mol. Cell Proteom. 15, 2448–2461 (2016).
doi: 10.1074/mcp.M116.059394
Vassilev, L. T. et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl Acad. Sci. USA 103, 10660–10665 (2006).
doi: 10.1073/pnas.0600447103 pubmed: 16818887 pmcid: 16818887
Murray, R. Z., Jolly, L. A. & Wood, S. A. The FAM deubiquitylating enzyme localizes to multiple points of protein trafficking in epithelia, where it associates with E-cadherin and beta-catenin. Mol. Biol. Cell 15, 1591–1599 (2004).
doi: 10.1091/mbc.e03-08-0630 pubmed: 379258 pmcid: 379258
Yang, B. et al. Deubiquitinase USP9X deubiquitinates beta-catenin and promotes high grade glioma cell growth. Oncotarget 7, 79515–79525 (2016).
pubmed: 5346732 pmcid: 5346732
Bansal, H. et al. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood 116, 4591–4599 (2010).
doi: 10.1182/blood-2009-10-247239 pubmed: 2996117 pmcid: 2996117
Kapuria, V. et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 70, 9265–9276 (2010).
doi: 10.1158/0008-5472.CAN-10-1530
Alfaro, C. et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat. Rev. 60, 24–31 (2017).
doi: 10.1016/j.ctrv.2017.08.004
Brew, R. et al. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 12, 78–85 (2000).
doi: 10.1006/cyto.1999.0518
Waugh, D. J. & Wilson, C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735–6741 (2008).
doi: 10.1158/1078-0432.CCR-07-4843
Kann, M. et al. WT1 targets Gas1 to maintain nephron progenitor cells by modulating FGF signals. Development 142, 1254–1266 (2015).
doi: 10.1242/dev.119735 pubmed: 4378252 pmcid: 4378252
Nakagama, H., Heinrich, G., Pelletier, J. & Housman, D. E. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol. Cell Biol. 15, 1489–1498 (1995).
doi: 10.1128/MCB.15.3.1489 pubmed: 230373 pmcid: 230373
Gales, D., Clark, C., Manne, U. & Samuel, T. The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol. 2013, 859154 (2013).
pubmed: 3810054 pmcid: 3810054
Guo, Y. et al. IL8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NFkappaB pathway in prostate cancer. Mol. Med. Rep. 16, 9035–9042 (2017).
doi: 10.3892/mmr.2017.7747
Fu, X. et al. Aberrant expression of deubiquitylating enzyme USP9X predicts poor prognosis in gastric cancer. Clin. Res. Hepatol. Gastroenterol. 41, 687–692 (2017).
doi: 10.1016/j.clinre.2017.01.008
Calvisi, D. F. et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 137, 1816–1826 (2009).
doi: 10.1053/j.gastro.2009.08.005
Gloeckner, C. J., Boldt, K., Schumacher, A. & Ueffing, M. Tandem affinity purification of protein complexes from mammalian cells by the Strep/FLAG (SF)-TAP tag. Methods Mol. Biol. 564, 359–372 (2009).
doi: 10.1007/978-1-60761-157-8_21
Parekh, S., Ziegenhain, C., Vieth, B., Enard, W. & Hellmann, I. The impact of amplification on differential expression analyses by RNA-seq. Sci. Rep. 6, 25533 (2016).
doi: 10.1038/srep25533 pubmed: 4860583 pmcid: 4860583
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
doi: 10.1186/s13059-014-0550-8 pubmed: 25516281 pmcid: 25516281

Auteurs

Michael Dietachmayr (M)

Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.
TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675, Munich, Germany.

Abirami Rathakrishnan (A)

Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.
TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675, Munich, Germany.

Oleksandra Karpiuk (O)

Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.
TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675, Munich, Germany.

Felix von Zweydorf (F)

German Center for Neurodegenerative Diseases (DZNE), 72076, Tübingen, Germany.

Thomas Engleitner (T)

TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675, Munich, Germany.
Department of Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Molecular Oncology and Functional Genomics, Technical University of Munich, Munich, Germany.

Vanesa Fernández-Sáiz (V)

Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.
TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675, Munich, Germany.

Petra Schenk (P)

Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.
TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675, Munich, Germany.

Marius Ueffing (M)

University of Tübingen, Center for Ophthalmology, Institute for Ophthalmic Research, 72076, Tübingen, Germany.

Roland Rad (R)

TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675, Munich, Germany.
Department of Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Molecular Oncology and Functional Genomics, Technical University of Munich, Munich, Germany.
Deutsches Konsortium für Translationale Krebsforschung (DKTK), 69120, Heidelberg, Germany.

Martin Eilers (M)

Theodor Boveri Institute, Department of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, 97074, Würzburg, Germany.

Christian Johannes Gloeckner (CJ)

German Center for Neurodegenerative Diseases (DZNE), 72076, Tübingen, Germany.
University of Tübingen, Center for Ophthalmology, Institute for Ophthalmic Research, 72076, Tübingen, Germany.

Katharina Clemm von Hohenberg (K)

Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany. k.clemm@dkfz-heidelberg.de.
Deutsches Krebsforschungszentrum (DKFZ), 69120, Heidelberg, Germany. k.clemm@dkfz-heidelberg.de.
CellNetworks Cluster of Excellence, University of Heidelberg, 69120, Heidelberg, Germany. k.clemm@dkfz-heidelberg.de.

Florian Bassermann (F)

Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany. florian.bassermann@tum.de.
TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675, Munich, Germany. florian.bassermann@tum.de.
Deutsches Konsortium für Translationale Krebsforschung (DKTK), 69120, Heidelberg, Germany. florian.bassermann@tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH